[14C]AZD9833 Oral Solution, 75 mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ER-positive, HER2-negative Breast Cancer
Conditions
ER-positive, HER2-negative Breast Cancer
Trial Timeline
May 10, 2022 → Jun 20, 2022
NCT ID
NCT05364255About [14C]AZD9833 Oral Solution, 75 mg
[14C]AZD9833 Oral Solution, 75 mg is a phase 1 stage product being developed by AstraZeneca for ER-positive, HER2-negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05364255. Target conditions include ER-positive, HER2-negative Breast Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05364255 | Phase 1 | Completed |
Competing Products
6 competing products in ER-positive, HER2-negative Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fulvestrant Run-In | Eli Lilly | Phase 2 | 52 |
| AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + Ribociclib | AstraZeneca | Phase 3 | 77 |
| AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonist | AstraZeneca | Phase 3 | 77 |
| AZD9833 + Fulvestrant | AstraZeneca | Phase 2 | 52 |
| Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab | Roche | Phase 1/2 | 41 |
| Onapristone + Fulvestrant | Context Therapeutics | Phase 2 | 44 |